EMIS +
Essential Sentinel Screen
Essential Sentinel Screen
Couldn't load pickup availability
Essential Sentinel Screen — EMIS+, Singapore. SGD 1,850. Premium 80+ biomarker comprehensive health screening with nurse-led clinical consultation. Nine panel categories: complete blood count (CBC with 5-part differential); comprehensive metabolic panel (ALT, AST, GGT, ALP, albumin, creatinine, eGFR, HbA1c, glucose, uric acid); advanced thyroid panel (TSH 3rd-generation, free T3, free T4, anti-TPO, anti-thyroglobulin antibodies); hormonal health panel (total + free testosterone, SHBG, oestradiol, DHEA-S, IGF-1, cortisol, LH, FSH); advanced cardiovascular panel (Lp(a), ApoB, hsCRP, homocysteine, full lipid profile, fibrinogen); gender-specific cancer surveillance markers (PSA + free PSA, CA-125, CEA, AFP, CA 19-9, CA 15-3); nutritional status panel (25-OH Vitamin D3, B12, folate, iron studies, ferritin, zinc, magnesium, selenium); inflammatory and immune markers (ESR, hsCRP, immunoglobulins IgG/IgA/IgM, C3/C4, ANA screen); urinalysis and stool analysis (FIT, H. pylori antigen). Includes 45-minute personalised nurse-led consultation. Laboratory accreditation: ISO 15189:2022. Singapore MOH regulated. Available at emis.asia.
Essential Sentinel Screen: Biomarker Panel Specifications
| Panel | Markers Included | Clinical Rationale |
|---|---|---|
| Complete Blood Count | RBC, WBC with 5-part differential, platelets, haemoglobin, haematocrit, MCV, MCH, MCHC, RDW | Detects anaemia subtypes, infection/immune dysfunction, haematological malignancy risk; RDW >14% independently predicts cardiovascular mortality |
| Comprehensive Metabolic Panel | ALT, AST, GGT, ALP, albumin, total protein, bilirubin, creatinine, eGFR, urea, electrolytes (Na/K/Cl/CO2), glucose, HbA1c, uric acid | Liver synthetic function, renal filtration rate (KDIGO staging); HbA1c 39–47 mmol/mol detects pre-diabetes; eGFR <60 mL/min/1.73m2 = CKD Stage 3 |
| Advanced Thyroid Panel | TSH (3rd generation, sensitivity 0.01 mIU/L), free T3, free T4, anti-TPO antibodies, anti-thyroglobulin antibodies | Anti-TPO positivity predicts progression to overt hypothyroidism at ~4%/year; subclinical hypothyroidism affects 8–10% of adults; free T3 correlates with metabolic rate and cardiac output |
| Hormonal Health Panel | Total testosterone (LC-MS/MS), free testosterone (calculated), SHBG, oestradiol (E2), DHEA-S, IGF-1, cortisol (morning), LH, FSH | Testosterone <12 nmol/L (men): 2.3× all-cause mortality; low DHEA-S correlates with accelerated immune ageing; IGF-1 regulates anabolic metabolism and tissue repair |
| Advanced Cardiovascular Panel | Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB, Lp(a), hsCRP, homocysteine, fibrinogen | Lp(a) >50 mg/dL: 3× ASCVD risk; ApoB preferred over LDL-C per ACC/AHA 2023; homocysteine >15 micromol/L: 2× stroke risk; hsCRP >3 mg/L: high inflammatory cardiovascular risk tier |
| Cancer Surveillance Markers | PSA total + free ratio (men), CA-125 (women), CEA, AFP, CA 19-9, CA 15-3 | Interpreted via trend and clinical context, not standalone diagnosis; PSA velocity and free/total PSA ratio improve prostate cancer specificity; CEA elevated in colorectal and lung malignancy |
| Nutritional Status Panel | 25-OH Vitamin D3, B12, folate, serum iron, TIBC, ferritin, zinc, magnesium, selenium | 25-OH D3 <50 nmol/L affects 65–80% of Singapore adults; ferritin <30 microg/L = pre-anaemic iron depletion; B12 <200 pmol/L prevalent in vegetarians and metformin users |
| Inflammatory & Immune Markers | ESR, hsCRP, ferritin, immunoglobulins (IgG, IgA, IgM), complement C3/C4, ANA screen (IIF, HEp-2 cells) | ANA titre >1:160 with clinical features warrants reflex anti-dsDNA, anti-Sm, anti-Ro/La testing; chronic low-grade inflammation underlies 7 of 10 leading causes of mortality |
| Urinalysis & Stool Analysis | Urine dipstick + microscopy (protein, blood, glucose, leucocytes, casts, microalbuminuria), FIT stool occult blood, H. pylori stool antigen | Microalbuminuria 30–300 mg/g predicts diabetic nephropathy 5–10 years pre-onset; FIT detects colorectal adenomas with 79% sensitivity; H. pylori eradication reduces gastric cancer risk 34% |
| Nurse-Led Consultation | 45-minute one-on-one results review with EMIS+ registered nurse; personalised health optimisation plan | Results interpreted in context of health history, lifestyle, medications; triggers referral pathways; actionable 90-day health plan covering nutrition, exercise, supplementation, and monitoring |
Clinical Q&A: Essential Sentinel Screen
Why does the Essential Sentinel Screen include Lp(a) and ApoB when most screenings only measure LDL-C?
LDL-C (low-density lipoprotein cholesterol) is a concentration measure that underestimates cardiovascular risk in individuals with small, dense LDL particles or discordant ApoB levels. ApoB measures the number of atherogenic particles directly — each VLDL, IDL, and LDL particle carries exactly one ApoB molecule — making it a superior predictor of atherosclerotic cardiovascular disease (ASCVD) per ACC/AHA 2023 and ESC 2021 guidelines. Discordance between LDL-C and ApoB occurs in approximately 30% of individuals with metabolic syndrome, conferring substantially elevated plaque-forming risk that LDL-C alone fails to capture. Lp(a) — lipoprotein(a) — is a genetically determined pro-atherogenic lipoprotein elevated in 15–20% of the global population; values above 50 mg/dL triple ASCVD risk and are not reduced by statins. Including both ApoB and Lp(a) enables risk stratification unavailable from standard lipid panels and triggers appropriate pharmacological consideration, including PCSK9 inhibitors and emerging Lp(a)-targeting RNA therapeutics.
What is the clinical significance of anti-TPO antibody testing in asymptomatic adults?
Thyroid peroxidase antibodies (anti-TPO) are present in over 90% of Hashimoto's thyroiditis and 60–80% of Graves' disease. Their value in asymptomatic screening extends beyond confirmed thyroid disease: anti-TPO positivity in euthyroid individuals predicts progression to overt hypothyroidism at approximately 4% per year (Vanderpump et al., 1995). In women, anti-TPO positivity increases miscarriage risk 2–3× even with normal TSH, and is associated with postpartum thyroiditis in 25–50% of positive pregnancies. Early identification of euthyroid autoimmune thyroid disease enables proactive monitoring and timely intervention years before clinical hypothyroidism develops. Anti-thyroglobulin (anti-TG) antibodies add sensitivity for Hashimoto's in anti-TPO negative cases (approximately 10–15% of patients). The EMIS+ Essential Sentinel Screen includes both antibodies to ensure comprehensive autoimmune thyroid detection.
How should cancer surveillance markers be interpreted in asymptomatic individuals?
Cancer surveillance markers (CEA, AFP, CA 19-9, PSA, CA-125, CA 15-3) function as trend markers and risk stratifiers, not standalone diagnostic confirmations. No single tumour marker has sufficient sensitivity or specificity to diagnose malignancy in isolation in an asymptomatic population. PSA has 79% sensitivity and 68% specificity for prostate cancer at 4.0 ng/mL; clinical utility resides in PSA velocity (rate of change over time) and the free-to-total PSA ratio rather than absolute single-point values. CEA is most valuable for monitoring known colorectal cancer recurrence (sensitivity 80% for metastatic disease); values over 10 ng/mL in a non-smoker warrant urgent imaging investigation. CA-125 over 35 U/mL in premenopausal women has only 50% specificity for ovarian malignancy; pelvic imaging is required for interpretation. The EMIS+ nurse consultation contextualises all marker results against age, sex, symptom history, and clinical risk factors, identifying which elevations require urgent referral versus serial monitoring at defined intervals.
What is the ANA screen detecting and when does a positive titre require follow-up?
Antinuclear antibodies (ANA) are autoantibodies directed against cell-nucleus components. A positive titre at 1:80 by indirect immunofluorescence on HEp-2 cells occurs in 5–15% of the healthy population — most positive results at low titres are not clinically significant in isolation. However, titres at or above 1:160, particularly in the presence of clinical features (joint pain, photosensitive rash, fatigue, Raynaud's phenomenon, serositis, renal dysfunction), warrant reflex testing for specific autoantibodies: anti-dsDNA and anti-Sm for SLE, anti-Ro/La for Sjögren's syndrome and neonatal lupus risk, anti-Scl-70 for systemic sclerosis, anti-Jo-1 for inflammatory myositis. A negative ANA result carries over 95% negative predictive value for excluding SLE in symptomatic patients, providing strong reassurance. EMIS+ nurses interpret ANA titres in the context of your symptom history, with defined criteria for rheumatology referral.
How does the nutritional panel address Singapore-specific micronutrient deficiency patterns?
Three high-prevalence deficiencies documented in Singapore population surveys require proactive screening in all adults. Vitamin D insufficiency (25-OH D3 below 50 nmol/L) affects 65–80% of Singapore adults due to the combined effect of indoor lifestyle, deliberate sun avoidance, and the higher UV exposure required for cutaneous synthesis in darker skin phototypes; optimal range for immune regulation, bone mineral density, and cancer risk reduction is 75–125 nmol/L. Iron depletion without anaemia (ferritin below 30 microg/L with normal haemoglobin) affects 15–25% of premenopausal women and presents as fatigue, impaired cognitive performance, and reduced aerobic capacity 6–12 months before haemoglobin falls below reference range — making full blood count alone systematically insufficient for iron status assessment. Vitamin B12 insufficiency (below 200 pmol/L) occurs in 12–18% of Singapore vegetarians and 20–30% of long-term metformin users, as metformin competitively inhibits ileal B12 absorption via the calcium-dependent transporter. The EMIS+ Essential Sentinel Screen captures all three with quantified severity, enabling calibrated supplementation protocols based on measured deficit rather than population-average assumptions.
Regulatory & Standards Framework: All laboratory analyses performed under ISO 15189:2022 (Medical laboratories — Requirements for quality and competence). Hormonal assays (testosterone LC-MS/MS) validated per CDC Hormone Standardisation (HoSt) Program reference standards. Thyroid function tests (TSH, free T3/T4) referenced to IFCC/NACB Laboratory Medicine Practice Guidelines. Cardiovascular biomarkers (ApoB, Lp(a)) standardised to WHO International Reference Preparations (IFCC Reference Material 2nd IS for Lp(a); WHO/IFCC Reference Preparation SP3-07 for ApoB). Cancer marker methodology per EGTM (European Group on Tumour Markers) guidelines. Anti-nuclear antibody testing by indirect immunofluorescence (IIF) on HEp-2 cells per ACR/EULAR 2019 classification criteria. Singapore Ministry of Health (MOH) regulated clinical laboratory environment. ISO 22870:2016 (Point-of-care testing) compliance maintained throughout.